Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
NCT02875002 · Yale University · PHASE1 · withdrawn · last registry update 2017-12-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-08-09Results posted on the registry: Boehringer Ingelheim, Volasertib + Volasertib (NCT02721875)
- 2018-08-09Also stopped (terminated): Boehringer Ingelheim, Volasertib + Volasertib (NCT02721875)
- 2018-08-06Results posted on the registry: Boehringer Ingelheim, Volasertib, low dose, d1q3w + Volasertib, middle dose, d1q3w (NCT01348347)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, BI 6727 + BIBF 1120 (NCT01022853)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, Azacitidine + Volasertib (NCT02201329)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, Volasertib (NCT01662505)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, volasertib (NCT01971476)
- 2018-05-04Also stopped (withdrawn): Massachusetts General Hospital, Volasertib + Cytarabine (NCT02905994)
- 2018-02-28Also stopped (terminated): University of Ulm, Volasertib + Cytarabine (NCT02198482)
- 2017-11-22Results posted on the registry: Boehringer Ingelheim, BI 6727, IV infusion (NCT01023958)
- 2017-04-05Also stopped (withdrawn): University of Alberta, Volasertib + Idarubicin (NCT02527174)
- 2017-01-27Also stopped (withdrawn): Boehringer Ingelheim, Volasertib (NCT02722135)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision